Moneycontrol PRO
Upcoming Event:Join us for New HorAIzon from Oct 6-7, 2pm and be a part of exciting conversations on tech & innovation
you are here: HomeNewsIndia

DCGI gives emergency approval to DRDO-developed 2-DG as adjunct therapy for COVID-19 patients

The drug was developed by the Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories

May 08, 2021 / 04:04 PM IST
India saw a record 4,187 fatalities due to COVID-19 in a single day, taking the country's death toll to 2,38,270, according to the Union health ministry data updated today (Representative image)

India saw a record 4,187 fatalities due to COVID-19 in a single day, taking the country's death toll to 2,38,270, according to the Union health ministry data updated today (Representative image)

The Drugs Controller General of India (DCGI) has granted permission for the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe OVID-19 cases, said Defence Research and Development Organisation (DRDO) on May 8.

The drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad, reported Hindustan Times.

According to the report, the results of the third phase of the clinical trial of the drug have shown that this molecule helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion, said the report.

The 2-DG comes in powder form in sachet and is taken orally by dissolving it in water.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"On May 01, DCGI granted permission for emergency use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country," the defence ministry said in a statement.

"It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique," the ministry said.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

India saw a record 4,187 fatalities due to COVID-19 in a single day, taking the country's death toll to 2,38,270, while 4,01,078 new infections were reported in a day, pushing the tally to 2,18,92,676, according to the Union Health Ministry data updated on the day. Registering a steady increase, the active cases have increased to 37,23,446, comprising 17.01 percent of the total infections, while the national COVID-19 recovery rate has dropped to 81.90 percent, the data updated at 8 am showed.

Amid the surge in COVID-19 cases, the drug seems to be of immense benefit to the people suffering from the infection.

(With PTI Inputs)

Follow our full coverage on COVID-19 here.

 
Moneycontrol News
first published: May 8, 2021 02:33 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark